Darunavir remains DHHS Guidelines recommended 3RD agent for treatment-naïve adult HIV-1 patients with uncertain adherence and in situations where resistance test results are not yet available
The Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents recognize the high genetic barrier to resistance of darunavir1
Darunavir-based regimens are the only non-integrase regimens with a DHHS AI or AII designation*1
A darunavir-based regimen is recommended for patients with uncertain adherence and inconsistent engagement in care†1
A darunavir-based regimen is recommended when antiretroviral therapy should be initiated before resistance test results are available1
Full DHHS Guidelines
* Darunavir/ritonavir (DRV/r) + tenofovir/emtricitabine=AI; darunavir/cobicistat (DRV/c) + tenofovir/emtricitabine=AII; DRV/r or DRV/c + abacavir/lamivudine=BII. A=strong; B=moderate; I=data from controlled randomized trials; II=data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes.
† Darunavir-based regimens are recommended initial regimens in certain clinical situations. One such situation is when a high genetic barrier to resistance is important because there is concern regarding a person’s adherence.
ARV=antiretroviral; DHHS=Department of Health and Human Services.
Reference: 1. Department of Health & Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.